Next Article in Journal
Deficits in Conditional Discrimination Learning in Children with ADHD Are Independent of Delay Aversion and Working Memory
Previous Article in Journal
Loss of Fibroblast-Dependent Androgen Receptor Activation in Prostate Cancer Cells is Involved in the Mechanism of Acquired Resistance to Castration
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JCM
Volume 8
Issue 9
10.3390/jcm8091380
Review Report
jcm-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Article
Peer-Review Record

Anti-Tumor Potential of a 5-HT3 Receptor Antagonist as a Novel Autophagy Inducer in Lung Cancer: A Retrospective Clinical Study with In Vitro Confirmation

J. Clin. Med. 2019, 8(9), 1380; https://doi.org/10.3390/jcm8091380
by Jeong Soo Lee 1,2,†, Seong Yong Park 3,†, Na Young Kim 1,2, Dong Wook Kim 4, Ju Eun Oh 2,*, Eunjin Heo 5, Jong Seok Lee 2,5 and Young Chul Yoo 1,2,*
Reviewer 1: Anonymous
Reviewer 2: Anonymous
J. Clin. Med. 2019, 8(9), 1380; https://doi.org/10.3390/jcm8091380
Submission received: 18 July 2019 / Revised: 22 August 2019 / Accepted: 2 September 2019 / Published: 3 September 2019
(This article belongs to the Section Oncology)

Round 1

Reviewer 1 Report

Title: Anti-tumour　potential　of　a　5-HT3　receptor　antagonist　as　a　novel　autophagy　inducer　in　lung　cancer:　A　retrospective clinical study with in vitro confirmation

The authors described the antitumor effect of 5-HT3RA in lung cancer. It is interesting and the manuscript has been well written. However, there are several issues to be addressed before accept.

The reason for selection of A549 lung cancer cell line should be explained. If possible, the data using other type of cell lines would be valuable. Some of the control group, designated as No P-R group, took ondansetron during the perioperative period. Ondansetron is one of the 5-HT3RA group and acted as an autophagy inducer via the ERK signaling pathway in this study, as well as palonosetron or ramosetron. Please show the correctness for the No P-R group of using ondansetron. There some misspelling in the text.

Author Response

Please see the attachment. 

Author Response File: Author Response.docx

Reviewer 2 Report

The authors instructions have been incorporated into the introduction and materials and methods and should be removed.

A fundamental issue with the patient selection should be addressed: in the NO PR group the patients may have had other antiemetic such as “meteclopramide, dexamethasone OR ondansetron” line 197. It is not clear whether patients in this group have been exposed to 5HT3RA in the form of ondansetron and we are not presented with any data on patients who have had no 5HT3RA at all. This may be because the numbers of available patients are very small (60 in this group), however this means that conclusions cannot be drawn.

The in vitro data demonstrate inhibition of proliferation, migration and clonogenicity with all 5HT3 antagonists albeit at concentrations higher than those used in clinical practice. Ondansetron does demonstrate activity (at higher concentrations) in all 3 assays and it is therefore important to determine whether patients were exposed to this drug in the NO PR group.

Given the uncertainty about the exposure to 5HT3 antagonists in the NO PR group and the small numbers of patients involved, no conclusions can be drawn and certainly no recommendations can be made about prospective use of palenosetron or ramosetron to reduce post operative recurrence of cancer without further studies.

Author Response

Please see the attachment. 

Author Response File: Author Response.docx

Round 2

Reviewer 1 Report

The authors responded to the comments properly.  The manuscript has been revised well.

Back to TopTop